谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.
研究兴趣

论文共 1362 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mesonephric-like Adenocarcinoma of the Female Genital Tract: Pathologic Diagnosis, Clinical Outcomes, and Novel Therapeutics
Kari L Ring,Anne M Mills, Brooke E Howitt, Rachel N Grisham,Elizabeth D Euscher,Hyun-Soo Kim,Ann H Klopp,David L Kolin,W Glenn McCluggage,Jelena Mirkovic,Kay J Park, Eliane Aoun, Chika Awujo,Ji Son, Samuel C Mok, Sammy Ferri-Borgogno,David S Hong,Lien Hoang, Amir A Jazaeri, Jeffrey A How,Karen H Lu
Gynecologic oncology (2025): 57-65
引用0浏览0WOS引用
0
0
Inhibitors of Oncogenic Kras Specifically Prime CTLA4 Blockade to Transcriptionally Reprogram Tregs and Overcome Resistance to Suppress Pancreas Cancer
Krishnan K Mahadevan, Ana S Maldonado,Bingrui Li, Aaron A Bickert, Adrian Perdyan, Shreyasee V Kumbhar,Sujan Piya, Amari Sockwell, Sami J Morse, Kent Arian,Hikaru Sugimoto,Shabnam Shalapour,David S Hong, Timothy P Heffernan,Anirban Maitra,Raghu Kalluri
bioRxiv the preprint server for biology (2025)
引用0浏览0WOS引用
0
0
Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial
Mirella Nardo, Camila Braganca Xavier,Bettzy Stephen, Jeffrey A How, Justin Moyers,Vivek Subbiah,David S Hong,Aung Naing
Journal of immunotherapy and precision oncologyno. 2 (2025): 143-151
引用0浏览0WOS引用
0
0
A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors
Lillian L Siu,David S Hong, Wolf-Dietrich Döcke, Reimo Tetzner,Mark Trautwein, Charles Phelps,Joerg Willuda, Xiang Qing Yu, Hendrik Nogai,Melissa Johnson,Boon Cher Goh
Targeted oncology (2025)
引用0浏览0WOS引用
0
0
Phase I Study of BMS-986299, an NLRP3 Agonist, As Monotherapy and in Combination with Nivolumab and Ipilimumab in Patients with Advanced Solid Tumors
Blessie E. Nelson,Shaun O'Brien, Rahul A. Sheth,David S. Hong,Aung Naing, Xiaoping Zhang,Amy Xu,Lora Hamuro, Rasika Suryawanshi, Derrick Mckinley, Ruslan D. Novosiadly, Sarina A. Piha-Paul
JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 1 (2025)
引用0浏览0WOS引用
0
0
加载更多
作者统计

#Papers: 1367

#Citation: 40213

H-Index: 95

G-Index: 175

Sociability: 9

Diversity: 3

Activity: 596

  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn